Related Experiment Video

Updated: Jun 18, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Real-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration

María José Olid-Cárdenas1,2,3, Alfonso Lendínez-Jurado3,4,5, Gabriela Monroy-Rodríguez6,7

  • 1Department of Marketing and Communication, Faculty of Communication, European University of Madrid, 28670 Villaviciosa de Odón, Spain.

Nutrients
|July 27, 2024
PubMed

Insights

Closed-loop systems effectively manage pediatric type 1 diabetes during summer camp, maintaining target glucose levels without increasing hypoglycemia or ketoacidosis risks, even with routine deviations.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Metabolic Disease Management

Background:

  • Closed-loop systems have transformed pediatric diabetes care.
  • Limited data exists on system performance during non-routine activities like summer camp.

Purpose of the Study:

  • To evaluate the safety and efficacy of closed-loop systems in pediatric type 1 diabetes patients during a summer camp.
  • To assess glucose control and system functionality during deviations from normal routines.

Main Methods:

  • A prospective, single-center preliminary study.
  • 27 pediatric type 1 diabetes patients (Medtronic MiniMed 780G and Tandem Control-IQ) were monitored during a 7-day camp and 3 weeks post-camp.
  • Key metrics included Time in Range (TIR), Time Below Range (TBR), and Time Above Range (TAR).

Main Results:

  • Target TIR of 70% was consistently met.
  • Worst TBR occurred at 72 hours; worst TAR in the first 24 hours, with subsequent improvement.
  • No severe hypoglycemia (Level 3) or diabetic ketoacidosis episodes were reported.

Conclusions:

  • Specific programming in closed-loop systems is safe for pediatric type 1 diabetes patients during summer camp.
  • These systems effectively manage glucose levels despite increased physical activity and altered feeding routines.
  • No increased risk of severe hypoglycemia or ketoacidosis was observed, regardless of the device used.

Keywords:
Medtronic MiniMedTM 780GTandem Control-IQadvanced hybrid closed loopdiabetes camppediatric type 1 diabetestime in hyperglycemiatime in range

More Related Videos

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

11.9K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.5K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
163
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
250
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
521
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
229